Bioengineering study demonstrates organ-on-a-chip screening of AAV vectors for blood–brain barrier penetration, suggesting improved delivery platforms for neurological gene therapies.
BBB model for scalable, high-throughput screening of gene therapies. These tools can drive investigations of the mechanisms underlying BBB permeability and the cell-type specificity of virus vectors.
No takes yet. Share an insight, caveat, or question.
Li et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: